| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
28,810,000 |
| Market
Cap: |
432.15(M) |
| Last
Volume: |
97,298 |
Avg
Vol: |
0 |
| 52
Week Range: |
$15 - $15 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AVEO Pharmaceuticals is a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines for patients with cancer. Co.'s product candidates include: Tivozanib, which is for the treatment of renal cell carcinoma, hepatocellular carcinoma, immunologically cold tumors and cholangiocarcinoma; Ficlatuzumab, which is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor; AV-380, which is a humanized IgG1 monoclonal antibody that targets growth differentiation factor 15; AV-203, which is a humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353, which is a IgG1 monoclonal antibody that targets the Notch 3 pathway.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dallas Matthew D |
VP, Finance |
• – – |
2015-01-07 |
4 |
AS |
$0.80 |
$415 |
D/D |
(519) |
17,581 |
|
- |
|
| Bailey Michael P |
President & CEO |
• • – |
2015-01-07 |
4 |
AS |
$0.80 |
$3,589 |
D/D |
(4,484) |
17,035 |
|
- |
|
| Gyuris Jeno |
SVP, Chief Scientific Officer |
• – – |
2015-01-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,200) |
80,615 |
|
- |
|
| Vittiglio Joseph |
SVP, General Counsel |
• – – |
2015-01-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,200) |
20,921 |
|
- |
|
| Dallas Matthew D |
VP, Finance |
• – – |
2015-01-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,485) |
18,100 |
|
- |
|
| Bailey Michael P |
President & CEO |
• • – |
2015-01-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,200) |
21,519 |
|
- |
|
| Evnin Anthony B |
Director |
– • – |
2015-01-02 |
4 |
A |
$0.88 |
$7,062 |
D/D |
8,025 |
38,881 |
|
- |
|
| Evnin Anthony B |
Director |
– • – |
2014-10-01 |
4 |
A |
$1.12 |
$7,062 |
D/D |
6,305 |
30,856 |
|
- |
|
| Dallas Matthew D |
VP, FinanceOfficer |
• – – |
2014-07-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
19,585 |
|
- |
|
| Evnin Anthony B |
Director |
– • – |
2014-07-01 |
4 |
A |
$1.81 |
$7,061 |
D/D |
3,901 |
24,551 |
|
- |
|
| Evnin Anthony B |
Director |
– • – |
2014-04-01 |
4 |
A |
$1.55 |
$7,062 |
D/D |
4,556 |
20,650 |
|
- |
|
336 Records found
|
|
Page 14 of 14 |
|
|
